AU695366B2 - Use of melatonin for treating patients suffering from drug addiction - Google Patents
Use of melatonin for treating patients suffering from drug addictionInfo
- Publication number
- AU695366B2 AU695366B2 AU44574/96A AU4457496A AU695366B2 AU 695366 B2 AU695366 B2 AU 695366B2 AU 44574/96 A AU44574/96 A AU 44574/96A AU 4457496 A AU4457496 A AU 4457496A AU 695366 B2 AU695366 B2 AU 695366B2
- Authority
- AU
- Australia
- Prior art keywords
- melatonin
- patient
- benzodiazepine drug
- benzodiazepine
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims description 109
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims description 106
- 229960003987 melatonin Drugs 0.000 title claims description 106
- 208000011117 substance-related disease Diseases 0.000 title description 4
- 206010013663 drug dependence Diseases 0.000 title description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 77
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 58
- 229940079593 drug Drugs 0.000 claims description 50
- 208000024891 symptom Diseases 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 16
- 229960003529 diazepam Drugs 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003607 modifier Substances 0.000 claims description 11
- 206010012335 Dependence Diseases 0.000 claims description 10
- 102000001419 Melatonin receptor Human genes 0.000 claims description 9
- 108050009605 Melatonin receptor Proteins 0.000 claims description 9
- 238000013270 controlled release Methods 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 7
- 229960002200 flunitrazepam Drugs 0.000 claims description 7
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 7
- 229960004535 oxazepam Drugs 0.000 claims description 7
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 6
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 6
- 229960004391 lorazepam Drugs 0.000 claims description 6
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims description 5
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 5
- 229960004538 alprazolam Drugs 0.000 claims description 5
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 5
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 5
- 229960004362 clorazepate Drugs 0.000 claims description 5
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 229960003528 flurazepam Drugs 0.000 claims description 5
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 5
- 229960004856 prazepam Drugs 0.000 claims description 5
- 229960003188 temazepam Drugs 0.000 claims description 5
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003386 triazolam Drugs 0.000 claims description 5
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002158 halazepam Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 26
- 230000027455 binding Effects 0.000 description 25
- 230000007958 sleep Effects 0.000 description 18
- 150000001557 benzodiazepines Chemical class 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 10
- QQEILXDLZRLTME-UHFFFAOYSA-N 6-sulfatoxymelatonin Chemical compound C1=C(OS(O)(=O)=O)C(OC)=CC2=C1NC=C2CCNC(C)=O QQEILXDLZRLTME-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 239000003326 hypnotic agent Substances 0.000 description 5
- 230000000147 hypnotic effect Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000004620 sleep latency Effects 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- -1 Halazepa Chemical compound 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 238000003350 crude synaptosomal preparation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000008454 sleep-wake cycle Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/381,535 US6469044B1 (en) | 1995-02-01 | 1995-02-01 | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| US381535 | 1995-02-01 | ||
| EP95303853A EP0724878B1 (en) | 1995-02-01 | 1995-06-06 | Use of melatonin for treating patients suffering from drug dependencies |
| EP95303853 | 1995-06-06 | ||
| PCT/IB1996/000082 WO1996023496A1 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treating patients suffering from drug addiction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4457496A AU4457496A (en) | 1996-08-21 |
| AU695366B2 true AU695366B2 (en) | 1998-08-13 |
Family
ID=26140195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU44574/96A Expired AU695366B2 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treating patients suffering from drug addiction |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JP4516159B2 (cs) |
| CN (1) | CN1083263C (cs) |
| AT (1) | AT408188B (cs) |
| AU (1) | AU695366B2 (cs) |
| BG (1) | BG62876B1 (cs) |
| BR (1) | BR9607169A (cs) |
| CZ (1) | CZ291349B6 (cs) |
| DK (1) | DK176081B1 (cs) |
| EE (1) | EE03384B1 (cs) |
| FI (1) | FI119586B (cs) |
| IS (1) | IS1980B (cs) |
| LU (1) | LU90118B1 (cs) |
| LV (1) | LV11940B (cs) |
| MD (1) | MD1716C2 (cs) |
| NO (1) | NO312814B1 (cs) |
| NZ (1) | NZ298878A (cs) |
| PL (1) | PL183148B1 (cs) |
| SI (1) | SI9620022A (cs) |
| SK (1) | SK284521B6 (cs) |
| TR (1) | TR199700723T1 (cs) |
| TW (1) | TW483757B (cs) |
| WO (1) | WO1996023496A1 (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996803B2 (ja) | 2000-01-05 | 2012-08-08 | ニューリム ファーマシューティカルズ（１９９１）リミテッド | 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物 |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| ES2646197T3 (es) | 2012-01-26 | 2017-12-12 | Vanda Pharmaceuticals Inc. | Tratamiento de trastornos del ritmo circadiano |
| WO2014100292A1 (en) | 2012-12-18 | 2014-06-26 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| SMT202000575T1 (it) * | 2016-10-31 | 2021-01-05 | Neurim Pharma 1991 | Minicompresse di melatonina e loro procedimenti di prepaazione |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2134789T3 (es) * | 1991-05-09 | 1999-10-16 | Neurim Pharma 1991 | Composiciones que contienen melatonina. |
| IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
-
1996
- 1996-01-29 BR BR9607169A patent/BR9607169A/pt not_active Application Discontinuation
- 1996-01-29 AT AT0901396A patent/AT408188B/de not_active IP Right Cessation
- 1996-01-29 NZ NZ298878A patent/NZ298878A/xx not_active IP Right Cessation
- 1996-01-29 WO PCT/IB1996/000082 patent/WO1996023496A1/en active IP Right Grant
- 1996-01-29 SI SI9620022A patent/SI9620022A/sl not_active IP Right Cessation
- 1996-01-29 JP JP52338596A patent/JP4516159B2/ja not_active Expired - Lifetime
- 1996-01-29 MD MD97-0254A patent/MD1716C2/ro not_active IP Right Cessation
- 1996-01-29 SK SK1030-97A patent/SK284521B6/sk unknown
- 1996-01-29 CZ CZ19972405A patent/CZ291349B6/cs not_active IP Right Cessation
- 1996-01-29 AU AU44574/96A patent/AU695366B2/en not_active Expired
- 1996-01-29 CN CN96191750A patent/CN1083263C/zh not_active Expired - Lifetime
- 1996-01-29 EE EE9700166A patent/EE03384B1/xx not_active IP Right Cessation
- 1996-01-29 PL PL96321630A patent/PL183148B1/pl unknown
- 1996-01-29 TR TR97/00723T patent/TR199700723T1/xx unknown
- 1996-04-12 TW TW085104319A patent/TW483757B/zh not_active IP Right Cessation
-
1997
- 1997-07-24 LV LVP-97-144A patent/LV11940B/en unknown
- 1997-07-25 IS IS4532A patent/IS1980B/is unknown
- 1997-07-30 BG BG101803A patent/BG62876B1/bg unknown
- 1997-07-30 DK DK199700896A patent/DK176081B1/da not_active IP Right Cessation
- 1997-07-31 FI FI973185A patent/FI119586B/fi not_active IP Right Cessation
- 1997-07-31 NO NO19973531A patent/NO312814B1/no not_active IP Right Cessation
- 1997-08-01 LU LU90118A patent/LU90118B1/fr active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0724878B1 (en) | Use of melatonin for treating patients suffering from drug dependencies | |
| Garfinkel et al. | Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs | |
| US20200253970A1 (en) | Method of Treating Metabolic Disorders and Depression with Dopamine Receptor Agonists | |
| AU695366B2 (en) | Use of melatonin for treating patients suffering from drug addiction | |
| Söderpalm et al. | Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration | |
| KR101000624B1 (ko) | 멜라토닌을 포함하는 약제학적 제제 | |
| US6344487B1 (en) | Treatment of insomnia | |
| Buydens-Branchey et al. | Craving for cocaine in addicted users: Role of serotonergic mechanisms | |
| JPH10513177A5 (cs) | ||
| CA2211839C (en) | Use of melatonin for treating patients suffering from drug addiction | |
| Zisapel | Development of a melatonin‐based formulation for the treatment of insomnia in the elderly | |
| HK1001218B (en) | Use of melatonin for treating patients suffering from drug dependencies | |
| Monteleone et al. | Lack of effect of short-term fluoxetine administration on nighttime plasma melatonin levels in healthy subjects | |
| MXPA97005856A (en) | Use of melatonine in the manufacture of unmedicament to deal with addiction to dro | |
| Hajak et al. | Clinical management of patients with insomnia: the role of zopiclone | |
| FUNCTIONING | SLEEP MORE! | |
| Conroy et al. | Sleep and substance use and abuse | |
| Bourin et al. | New approaches to panic disorder | |
| Wasielewski | Attenuation of alcohol-induced circadian phase-shifts using melatonin and vitamin B12 |